Showing 1361-1370 of 5771 results for "".
- Opthea Announces Executive Leadership Changes and Senior Hireshttps://modernod.com/news/opthea-announces-executive-leadership-changes-and-senior-hires/2482429/Opthea announced several executive leadership changes aimed at bolstering the company’s commercial and clinical expertise as it prepares for the anticipated 2025 topline data readout of phase 3 trials for its lead candidate, sozinibercept, in wet AMD. Daniel Geffken, Co-Founder an
- Bausch + Lomb Announces New Scientific Data, Educational Events at ESCRShttps://modernod.com/news/bausch-lomb-announces-new-scientific-data-educational-events-at-escrs/2482419/Bausch + Lomb will present new scientific data and educational events at the European Society of Cataract and Refractive Surgery (ESCRS) annual meeting in Barcelona, Spain, September 6-10. Scientific posters and papers will highlight the results of studies evaluating Baus
- Former Regenxbio Execs Announce Launch of Gene Therapy Company Tern Therapeuticshttps://modernod.com/news/former-regenxbio-execs-announce-launch-of-gene-therapy-company-turn-therapeutics/2482414/Tern Therapeutics announced its official launch alongside the successful closing of a $15 million financing round. Simultaneously, Tern revealed a global licensing agreement with Regenxbio to acquire two gene therapy programs—RGX-381 and RGX-181—now designated as TTX-381 and
- Aura Biosciences to Present Phase 2 Data on Belzupacap Sarotalocan for Choroidal Melanoma at Retina Society Annual Meetinghttps://modernod.com/news/aura-biosciences-to-present-phase-2-data-on-belzupacap-sarotalocan-for-choroidal-melanoma-at-retina-society-annual-meeting/2482412/Aura Biosciences announced that final data from its phase 2 study on the suprachoroidal administration of belzupacap sarotalocan (bel-sar) for treating small choroidal melanoma and indeterminate lesions will be presented at the Retina Society Annual Meeting. The event will take place from Septemb
- Ocutech Announces Release of SideSight Ultrasonic Sensor Device for Homonymous Hemianopiahttps://modernod.com/news/ocutech-announces-limited-release-of-sidesight-ultrasonic-sensor-device-for-homonymous-hemianopia/2482405/Ocutech announced the limited first release of its new ultrasonic sensor device, the SideSight. Developed in collaboration with experts in electrical, software, and mechanical engineering, Ocutech says the SideSight is designed to assist individuals who have experienced loss of side vision, a con
- Contact Lens Institute Opens Nominations for Second Annual Culture Awardshttps://modernod.com/news/contact-lens-institute-opens-nominations-for-second-annual-culture-awards/2482394/The Contact Lens Institute (CLI) has announced that nominations for the second annual CLI Culture Awards are now open, with submissions being accepted through October 1, 2024. This program aims to recognize eye care professionals who are committed to fostering a positive culture around contact le
- LumiThera Announces First CPT Code to Report Photobiomodulation Therapy in Retinal Diseasehttps://modernod.com/news/lumithera-announces-first-cpt-code-to-report-photobiomodulation-therapy-in-retinal-disease/2482389/LumiThera announced a new Category III CPT code, effective January 1, 2025. The code, "Photobiomodulation therapy of retina, single session,” was approved by the AMA’s CPT Editorial Panel at the May 2024 meeting.[1] The LIGHTSITE III clinical trial was a
- Annexon Provides Update on ARCHER II Global Registrational Program in GAhttps://modernod.com/news/annexon-provides-update-on-archer-ii-global-registrational-program-in-geographic-atrophy/2482386/Annexon announced patient dosing was initiated in the global pivotal phase 3 ARCHER II trial evaluating ANX007 for the treatment of geographic atrophy (GA). The company says the trial is the only GA pivotal program utilizing visual protection as the global regulatory-aligned primary end
- Nicox Announces Recruitment of Last Patient in US in Denali Phase 3 Trial of NCX 470https://modernod.com/news/nicox-announces-recruitment-of-last-patient-in-us-in-denali-phase-3-trial-of-ncx-470/2482375/Nicox announced the recruitment and randomization of the last patient in the United States in its Denali phase 3 trial of NCX 470. The Denali trial is evaluating NCX 470 safety and efficacy in patients with open-angle glaucoma or ocular hypertension. Ac
- Nova Eye to Feature Several Presentations and Posters Related to iTrack Canaloplasty at 2024 ESCRS Annual Congresshttps://modernod.com/news/nova-eye-to-feature-several-presentations-and-posters-related-to-itrack-canaloplasty-at-2024-escrs-annual-congress/2482374/Nova Eye Medical has announced that the company’s proprietary canaloplasty technology platform (iTrack and iTrack Advance) will be featured in numerous presentations and posters during the official scientific program of the European Society of Cataract and Refractive Surgeons